Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Brief report: lack of response in an autistic population to a low dose clinical trial of pyridoxine plus magnesium.

Tolbert L, Haigler T, Waits MM, Dennis T.

J Autism Dev Disord. 1993 Mar;23(1):193-9. No abstract available.

PMID:
8463199
2.

Effects of pyridoxine and magnesium on autistic symptoms--initial observations.

Lelord G, Muh JP, Barthelemy C, Martineau J, Garreau B, Callaway E.

J Autism Dev Disord. 1981 Jun;11(2):219-30.

PMID:
6765503
3.

The effect of high doses of vitamin B6 on autistic children: a double-blind crossover study.

Rimland B, Callaway E, Dreyfus P.

Am J Psychiatry. 1978 Apr;135(4):472-5.

PMID:
345827
4.

[Biological and clinical effects of oral magnesium and associated magnesium-vitamin B6 administration on certain disorders observed in infantile autism (author's transl)].

Barthelemy C, Garreau B, Leddet I, Sauvage D, Domenech J, Muh JP, Lelord G.

Therapie. 1980 Sep-Oct;35(5):627-32. French. No abstract available.

PMID:
7010662
5.

[Clinical and biochemical value of Magnesium + vitamin B6 combination in the treatment of residual autism in adults].

Jonas C, Etienne T, Barthélemy C, Jouve J, Mariotte N.

Therapie. 1984 Nov-Dec;39(6):661-9. French. No abstract available.

PMID:
6397868
6.

Vitamin B6, magnesium, and combined B6-Mg: therapeutic effects in childhood autism.

Martineau J, Barthelemy C, Garreau B, Lelord G.

Biol Psychiatry. 1985 May;20(5):467-78.

PMID:
3886023
7.

Brief report: an open middle-term study of combined vitamin B6-magnesium in a subgroup of autistic children selected on their sensitivity to this treatment.

Martineau J, Barthelemy C, Cheliakine C, Lelord G.

J Autism Dev Disord. 1988 Sep;18(3):435-47. No abstract available.

PMID:
3170459
8.

High-dose pyridoxine and magnesium administration in children with autistic disorder: an absence of salutary effects in a double-blind, placebo-controlled study.

Findling RL, Maxwell K, Scotese-Wojtila L, Huang J, Yamashita T, Wiznitzer M.

J Autism Dev Disord. 1997 Aug;27(4):467-78.

PMID:
9261669
9.

Critique of "Efficacy of vitamin B6 and magnesium in the treatment of autism".

Rimland B.

J Autism Dev Disord. 1998 Dec;28(6):580-1. No abstract available.

PMID:
9932246
10.

Clinical and biological effects of high doses of vitamin B6 and magnesium on autistic children.

Lelord G, Callaway E, Muh JP.

Acta Vitaminol Enzymol. 1982;4(1-2):27-44.

PMID:
7124567
11.

High dose vitamin B6 and magnesium in treating autism: response to study by Findling et al.

Rimland B.

J Autism Dev Disord. 1998 Dec;28(6):581-2. No abstract available.

PMID:
9932247
12.

[Value of behavior scales and urinary homovanillic acid determinations in monitoring the combined treatment with vitamin B6 and magnesium of children displaying autistic behavior].

Barthélémy C, Garreau B, Leddet I, Sauvage D, Muh JP, Lelord G, Callaway E.

Neuropsychiatr Enfance Adolesc. 1983 May-Jun;31(5-6):289-301. French. No abstract available.

PMID:
6888687
13.

Electrophysiological effects of fenfluramine or combined vitamin B6 and magnesium on children with autistic behaviour.

Martineau J, Barthelemy C, Roux S, Garreau B, Lelord G.

Dev Med Child Neurol. 1989 Dec;31(6):721-7.

PMID:
2599266
14.

The vitamin and mineral mystery.

Strayhorn JM.

J Am Acad Child Adolesc Psychiatry. 1994 Nov-Dec;33(9):1346-7. No abstract available.

PMID:
7995802
15.

Controversies in the treatment of autistic children: vitamin and drug therapy.

Rimland B.

J Child Neurol. 1988;3 Suppl:S68-72. Review.

PMID:
3058789
16.

Long-term effects of combined vitamin B6-magnesium administration in an autistic child.

Martineau J, Barthelemy C, Lelord G.

Biol Psychiatry. 1986 May;21(5-6):511-8. No abstract available.

PMID:
3083877
17.

Efficacy of vitamin B6 and magnesium in the treatment of autism: a methodology review and summary of outcomes.

Pfeiffer SI, Norton J, Nelson L, Shott S.

J Autism Dev Disord. 1995 Oct;25(5):481-93. Review.

PMID:
8567594
18.

Effects of vitamin B6 on averaged evoked potentials in infantile autism.

Martineau J, Garreau B, Barthelemy C, Callaway E, Lelord G.

Biol Psychiatry. 1981 Jul;16(7):627-41.

PMID:
7272379
20.

[Acceptability and short-term tolerance to an orally administered new formulation of magnesium (TX 1341) compared to that of a reference magnesium].

Paccalin J, Gelas B, Herbrecht F, Torres C, Chevallier T, Micheletti MC.

Presse Med. 1998 Mar 14;27(10):476. French. No abstract available.

PMID:
9767980

Supplemental Content

Support Center